Circulating microRNA-126 in patients with ischemic heart disease with type 2 diabetes mellitus and its relationship with glucometabolic disorders

The aim of the study was to investigate circulating microRNA-126-3p levels and its relationships with glucometabolic indices in patients with ischemic heart disease (IHD) and type 2 diabetes mellitus (Т2DM). Materials and methods. The study included 68 patients with stable coronary artery disease...

Full description

Saved in:
Bibliographic Details
Main Authors: S. A. Serik, N. R. Mavrycheva, T. M. Bondar
Format: Article
Language:English
Published: Zaporizhzhia State Medical and Pharmaceutical University 2022-11-01
Series:Zaporožskij Medicinskij Žurnal
Subjects:
Online Access:http://zmj.zsmu.edu.ua/article/view/257413/262724
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849739039853248512
author S. A. Serik
N. R. Mavrycheva
T. M. Bondar
author_facet S. A. Serik
N. R. Mavrycheva
T. M. Bondar
author_sort S. A. Serik
collection DOAJ
description The aim of the study was to investigate circulating microRNA-126-3p levels and its relationships with glucometabolic indices in patients with ischemic heart disease (IHD) and type 2 diabetes mellitus (Т2DM). Materials and methods. The study included 68 patients with stable coronary artery disease (CAD) and T2DM, 25 CAD patients without diabetes and 18 healthy individuals as a control. MiRNA126-3p was determined in blood plasma by real time polymerase chain reaction. Small nuclear RNA U6 was used as an endogenous control. Results. Circulating miRNA-126-3p levels in CAD patients both with T2DM (50.32 [19.54; 93.82]) and without diabetes (109.46 [49.52; 211.11]) were higher than in the controls (17.95 [13.74; 35.01]) (P = 0.018 and P < 0.001). But in patients with T2DM, miRNA126-3p level was decreased in comparison with patients without diabetes (P < 0.001). In patients with T2DM, miRNA-126-3p displayed a significant negative correlation with blood glucose level (R = -0.259, P = 0.037) and was correlated negatively with glycosylated hemoglobin (R = -0.246, Р = 0.056) and insulin resistance index HOMA-IR (R = -0.229, P = 0.082) reaching boundary level of statistical significance. In diabetic patients, lower miRNA-126-3p level (the 1st tertile) was associated with a significant increase in blood glucose level and HOMA-IR in comparison with the 3rd tertile (P = 0.011 and P = 0.041). According to the ROC-analysis, the decrease in miRNA-126-3p levels was significantly associated with the presence of T2DM in patients with САD: AUC was 0.734 (95 % CI: 0.631–0.822, P < 0.001). Conclusions. Circulating miRNA-126-3p levels in CAD patients both with and without T2DM were increased compared to the controls, possibly due to compensatory mechanisms. However, in patients with T2DM, miRNA-126-3p expression was significantly lower than in patients without T2DM. The lowest miRNA-126-3p level in CAD patients with T2DM was associated with the significant elevation of blood glucose level and the increase in insulin resistance. MiRNA-126-3p may serve as potential biomarker for predicting and early diagnosis of T2DM in patients with CAD.
format Article
id doaj-art-f542b504a69f43c5a2e4353a9b5cedea
institution DOAJ
issn 2306-4145
2310-1210
language English
publishDate 2022-11-01
publisher Zaporizhzhia State Medical and Pharmaceutical University
record_format Article
series Zaporožskij Medicinskij Žurnal
spelling doaj-art-f542b504a69f43c5a2e4353a9b5cedea2025-08-20T03:06:24ZengZaporizhzhia State Medical and Pharmaceutical UniversityZaporožskij Medicinskij Žurnal2306-41452310-12102022-11-0124550150810.14739/2310-1210.2022.5.257413Circulating microRNA-126 in patients with ischemic heart disease with type 2 diabetes mellitus and its relationship with glucometabolic disordersS. A. Serik0https://orcid.org/0000-0001-6257-3566N. R. Mavrycheva1https://orcid.org/0000-0001-7967-4179T. M. Bondar2https://orcid.org/0000-0002-2501-317XGI “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”, KharkivGI “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”, KharkivGI “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”, KharkivThe aim of the study was to investigate circulating microRNA-126-3p levels and its relationships with glucometabolic indices in patients with ischemic heart disease (IHD) and type 2 diabetes mellitus (Т2DM). Materials and methods. The study included 68 patients with stable coronary artery disease (CAD) and T2DM, 25 CAD patients without diabetes and 18 healthy individuals as a control. MiRNA126-3p was determined in blood plasma by real time polymerase chain reaction. Small nuclear RNA U6 was used as an endogenous control. Results. Circulating miRNA-126-3p levels in CAD patients both with T2DM (50.32 [19.54; 93.82]) and without diabetes (109.46 [49.52; 211.11]) were higher than in the controls (17.95 [13.74; 35.01]) (P = 0.018 and P < 0.001). But in patients with T2DM, miRNA126-3p level was decreased in comparison with patients without diabetes (P < 0.001). In patients with T2DM, miRNA-126-3p displayed a significant negative correlation with blood glucose level (R = -0.259, P = 0.037) and was correlated negatively with glycosylated hemoglobin (R = -0.246, Р = 0.056) and insulin resistance index HOMA-IR (R = -0.229, P = 0.082) reaching boundary level of statistical significance. In diabetic patients, lower miRNA-126-3p level (the 1st tertile) was associated with a significant increase in blood glucose level and HOMA-IR in comparison with the 3rd tertile (P = 0.011 and P = 0.041). According to the ROC-analysis, the decrease in miRNA-126-3p levels was significantly associated with the presence of T2DM in patients with САD: AUC was 0.734 (95 % CI: 0.631–0.822, P < 0.001). Conclusions. Circulating miRNA-126-3p levels in CAD patients both with and without T2DM were increased compared to the controls, possibly due to compensatory mechanisms. However, in patients with T2DM, miRNA-126-3p expression was significantly lower than in patients without T2DM. The lowest miRNA-126-3p level in CAD patients with T2DM was associated with the significant elevation of blood glucose level and the increase in insulin resistance. MiRNA-126-3p may serve as potential biomarker for predicting and early diagnosis of T2DM in patients with CAD. http://zmj.zsmu.edu.ua/article/view/257413/262724coronary artery diseasetype 2 diabetes mellitusmiсrornablood glucoseinsulin resistance
spellingShingle S. A. Serik
N. R. Mavrycheva
T. M. Bondar
Circulating microRNA-126 in patients with ischemic heart disease with type 2 diabetes mellitus and its relationship with glucometabolic disorders
Zaporožskij Medicinskij Žurnal
coronary artery disease
type 2 diabetes mellitus
miсrorna
blood glucose
insulin resistance
title Circulating microRNA-126 in patients with ischemic heart disease with type 2 diabetes mellitus and its relationship with glucometabolic disorders
title_full Circulating microRNA-126 in patients with ischemic heart disease with type 2 diabetes mellitus and its relationship with glucometabolic disorders
title_fullStr Circulating microRNA-126 in patients with ischemic heart disease with type 2 diabetes mellitus and its relationship with glucometabolic disorders
title_full_unstemmed Circulating microRNA-126 in patients with ischemic heart disease with type 2 diabetes mellitus and its relationship with glucometabolic disorders
title_short Circulating microRNA-126 in patients with ischemic heart disease with type 2 diabetes mellitus and its relationship with glucometabolic disorders
title_sort circulating microrna 126 in patients with ischemic heart disease with type 2 diabetes mellitus and its relationship with glucometabolic disorders
topic coronary artery disease
type 2 diabetes mellitus
miсrorna
blood glucose
insulin resistance
url http://zmj.zsmu.edu.ua/article/view/257413/262724
work_keys_str_mv AT saserik circulatingmicrorna126inpatientswithischemicheartdiseasewithtype2diabetesmellitusanditsrelationshipwithglucometabolicdisorders
AT nrmavrycheva circulatingmicrorna126inpatientswithischemicheartdiseasewithtype2diabetesmellitusanditsrelationshipwithglucometabolicdisorders
AT tmbondar circulatingmicrorna126inpatientswithischemicheartdiseasewithtype2diabetesmellitusanditsrelationshipwithglucometabolicdisorders